[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mansoura University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":670},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,103,0,25,[9,48,76,105,135,170,194,228,249,274,301,330,357,376,400,424,450,480,505,524,545,565,591,617,643],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645193","custom-made-peek-versus-ptfe-membranes-in-maxillary-alveolar-ridge-augmentation-100645193",false,"NCT07679451","Custom-Made PEEK Versus PTFE Membranes in Maxillary Alveolar Ridge Augmentation","Custom-Made Polyether Ether Ketone Membrane Versus Polytetrafluoroethylene Membrane in Maxillary Alveolar Ridge Augmentation: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nAge between 20 and 45 years. Male or female participants. Presence of single or multiple missing teeth associated with vertical alveolar defects (vertical bone height less than 8 mm), horizontal alveolar defects (ridge width less than 6 mm), or combined defects in the maxillary esthetic zone requiring alveolar ridge augmentation before implant placement.\n\nGood oral hygiene.\n\nExclusion Criteria:\n\nUncontrolled medical disorders contraindicating surgical intervention. Systemic diseases or medications affecting bone metabolism. Current or previous bisphosphonate therapy. History of radiotherapy. History of chemotherapy. Smokers.","ALL","20 Years","45 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled clinical study aims to evaluate and compare the effectiveness of custom-made polyether ether ketone (PEEK) membranes versus polytetrafluoroethylene (PTFE) membranes in guided bone regeneration for maxillary alveolar ridge augmentation in the esthetic zone. Thirty patients requiring ridge augmentation prior to dental implant placement will be enrolled and randomly allocated into two equal groups. Group A will receive customized PEEK membranes, while Group B will be treated with PTFE membranes. Clinical and radiographic assessments, including cone beam computed tomography (CBCT), will be performed immediately postoperatively, at 6 months, and at 12 months to evaluate volumetric, horizontal, and vertical bone gain as well as soft tissue healing and complication rates.",[28],"Alveolar Ridge Deficiency",[30,31,32,33,34],"Guided Bone Regeneration","PEEK membrane","PTFE membrane","Ridge augmentation","Maxillary ridge augmentation","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2026-01-01",{"date":43,"type":22},"2027-02-01",{"name":45,"class":46},"Mansoura University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100644467","early-phase-1-comparison-of-the-efficacy-of-conventional-versus-minimally-invasive-non-surgical-periodontal-therapy-in-periodontitis-patients-100644467","NCT07671274","Comparison of the Efficacy of Conventional Versus Minimally Invasive Non-Surgical Periodontal Therapy in Periodontitis Patients","Comparison of the Efficacy of Conventional Versus Minimally Invasive Non-Surgical Periodontal Therapy in Periodontitis Patients (Randomized Controlled Clinical Trial)","Inclusion Criteria:\n\n* • Patients with stage III pericdontitis, according to the American Academy of Periodontology (AAP) and the European Federation of Periodontology (EFP) periodontal classification system .\n\n  * Medically free patients.\n  * Non-smokers\n  * Patients with good oral hygiene.\n\nExclusion Criteria:\n\n* Pregnant or lactating females.\n\n  * Patients with systemic diseases that might affect periodontal health\n  * previous periodontal treatment within 6 months before baseline examination.\n  * prior antibiotic regimen use within 1 month before baseline examination",true,"40 Years",{"count":21,"type":22},[59],"EARLY_PHASE1","the aim of this study is to investigate the clinical outcomes of Minimally Invasive Non-Surgical Therapy(MINST) compared to Conventional non-surgical periodontal therapy (CNST)",[62,63],"Periodontal Disease","Stage III Periodontitis",[65,66,67],"periodontitis","stage III","mechanical debridement","2026-06-24",{"date":70,"type":39},"2026-06-26",{"date":72,"type":39},"2025-08-05",{"date":74,"type":22},"2026-08-05",{"name":45,"class":46},{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100641414","effect-of-marital-adjustment-strategies-on-emotional-divorce-among-married-women-100641414","NCT07652411","Effect of Marital Adjustment Strategies on Emotional Divorce Among Married Women","Appling Marital Adjustment Strategies for Emotionally Divorced Wives","Inclusion criteria:\n\n* Free from any medical and psychological disorders.\n* couples are committed to staying in one house despite emotional divorce or not.\n* wives married for 2 years, the family had children who were both spouses and not children of either spouse.\n\nExclusion criteria:\n\n* Age ≤ (18 or ≥ 55) years.\n* Illegal marriage.","FEMALE","18 Years","55 Years",{"count":87,"type":22},320,[25],"Aim: The current study aims to evaluate the impact of marital adjustment strategies on emotional divorce among married women.\n\nDesign: A mixed design consisting of a cross-sectional study and a quasi-experimental one-group pre-test\u002Fpost-test design.\n\nSample: A purposive sample of 320 married women.\n\nSetting: Antenatal Outpatient Clinics at the New Obstetrics and Gynecology Hospital, Mansoura University Hospitals, Egypt.\n\nTools: Data will be collected using three tools: a structured interview questionnaire, the Emotional Divorce Scale, and the Marital Adjustment Strategies Scale.\n\nIntervention: Participants will receive a structured marital adjustment strategies program delivered through educational sessions designed to address communication, coping, emotional expression, problem-solving, and marital adjustment strategies.\n\nOutcome Measures: Emotional divorce levels and marital adjustment strategies will be assessed at baseline and after completion of the intervention according to the study protocol.",[91],"Marital Relationship",[93,94,95],"Emotional Divorce","Marital Relations","Marital Adjustment Strategies","NOT_YET_RECRUITING","2026-06-16",{"date":99,"type":39},"2026-06-17",{"date":101,"type":22},"2026-12-11",{"date":103,"type":22},"2027-11-11",{"name":45,"class":46},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":47},"100609456","phase-2-sglt2-inhibitors-in-adult-primary-nephrotic-syndrome-100609456","NCT07214818","SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome","Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Adult Patients With Nephrotic Syndrome: A Randomized Controlled Trial","SGLT2-NS","Inclusion Criteria:\n\nAdult patients (≥18 years). Biopsy-confirmed primary nephrotic syndrome (e.g., idiopathic membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis).\n\nEstimated glomerular filtration rate (eGFR) ≥25 mL\u002Fmin\u002F1.73m² using CKD-EPI formula.\n\nOn stable dose of immunosuppressive therapy and renoprotective agents for ≥4 weeks prior to randomization.\n\nAble to signed informed consent.\n\nExclusion Criteria:\n\nDiagnosis of secondary nephrotic syndrome as : diabetes mellitus, lupus nephritis, and amyloidosis.\n\n* Impaired liver functions (ALT or AST values exceeding 3 folds upper limit of normal (ULN) at the screening visit).\n* Glomerular hematuria (red blood cells more than ten cells per high power field (HPF) after routine urinalysis for more than three times in the last 2 weeks).\n* History of severe hypersensitivity or contraindications to dapagliflozin or empagliflozine.\n* Pregnancy or breastfeeding.",{"count":114,"type":22},75,[116,117],"PHASE2","PHASE3","This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome. The study will compare three groups: dapagliflozin plus standard therapy, empagliflozin plus standard therapy, and standard therapy alone.\n\nThe primary objective is to assess whether SGLT2 inhibitors reduce proteinuria, maintain remission, and prevent relapse. Secondary objectives include evaluating effects on kidney function (eGFR, serum creatinine) and monitoring safety outcomes.\n\nParticipants will continue their baseline standard care and will be followed for 6 months with regular clinical evaluations, laboratory tests, and adverse event monitoring.",[120],"Nephrotic Syndrome",[122,123,124,125,126],"SGLT2 inhibitors","Dapagliflozin","Empagliflozin","Proteinuria","Primary Nephrotic Syndrome","2026-06-08",{"date":129,"type":39},"2026-06-09",{"date":131,"type":39},"2025-11-15",{"date":133,"type":22},"2026-09-06",{"name":45,"class":46},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":19,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":147,"conditions":148,"keywords":153,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":47},"100643446","phase-4-carbetocin-monotherapy-versus-carbetocin-plus-oxytocin-infusion-in-elective-cesarean-delivery-a-non-inferiority-trial-100643446","NCT07636421","Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial","Comparative Efficacy of Carbetocin Monotherapy Versus Carbetocin With Supplemental Oxytocin Infusion in Maintaining Uterine Tone and Preventing Blood Loss in Elective Cesarean Delivery: A Randomized, Double-Blind, Non-Inferiority Controlled Trial","CARBOXY-RCT","Inclusion Criteria:\n\n* Adult women aged 18 to 45 years\n* Scheduled for elective non-emergency cesarean delivery\n* Spinal anesthesia planned and administered as the sole anesthetic technique\n* Singleton pregnancy at gestational age of 37 completed weeks or more\n* ASA physical status II\n* Preoperative hemoglobin of 9 g\u002FdL or more\n* Able to provide written informed consent in Arabic or English\n\nExclusion Criteria:\n\n* Emergency or crash cesarean delivery\n* Placenta previa, placenta accreta spectrum disorder, or other abnormal placentation\n* Known uterine anomalies likely to impair contractility including fibroids greater than 5 cm, bicornuate or unicornuate uterus\n* Grand multiparity defined as 5 or more previous deliveries\n* Multiple gestation including twins or higher order\n* Polyhydramnios defined as amniotic fluid index greater than 24 cm\n* Prior oxytocin augmentation in current pregnancy for more than 6 hours\n* Known hypersensitivity to carbetocin, oxytocin, or any formulation excipient\n* Severe preeclampsia, eclampsia, or HELLP syndrome\n* Cardiovascular disease including arrhythmia, valvular disease, cardiomyopathy, or ischemic heart disease\n* Known coagulopathy or thrombocytopenia with platelets less than 100 x 10\\^9\u002FL\n* Hepatic or renal impairment\n* Body mass index greater than 40 kg\u002Fm2 at time of delivery\n* Enrollment in another interventional clinical trial",{"count":144,"type":22},332,[146],"PHASE4","Background: Carbetocin is an established single-dose uterotonic agent for postpartum hemorrhage prophylaxis at elective cesarean delivery. Despite its proven efficacy, many clinicians routinely add a supplemental oxytocin infusion following carbetocin administration without evidence-based justification. Concurrent oxytocin receptor stimulation may be redundant, counterproductive through receptor desensitization, or incrementally beneficial - a mechanistic uncertainty that remains unresolved in the published literature.\n\nObjectives: To determine whether carbetocin monotherapy (100 micrograms IV bolus plus placebo infusion) is non-inferior to carbetocin plus supplemental oxytocin infusion (10 IU over 4 hours) in preventing the need for additional uterotonic agents within 24 hours of elective cesarean delivery.\n\nStudy Design: Prospective, randomized, double-blind, placebo-controlled, non-inferiority trial with an integrated pilot phase. Phase 1 (Pilot, n=60) establishes local feasibility and event rate. Phase 2 (Full trial, n=332) provides the definitive non-inferiority analysis.\n\nParticipants: Women aged 18-45 years undergoing elective cesarean delivery under spinal anesthesia at Qassim University Medical City, singleton pregnancy at or beyond 37 weeks, ASA physical status II, preoperative hemoglobin 9 g\u002FdL or more.\n\nInterventions: Group C (Monotherapy): Carbetocin 100 micrograms IV bolus plus placebo saline infusion 500 mL over 4 hours. Group C+O (Combination): Carbetocin 100 micrograms IV bolus plus oxytocin 10 IU in 500 mL saline over 4 hours.\n\nPrimary Outcome: Proportion of patients requiring at least one additional uterotonic agent within 24 hours of delivery.\n\nSecondary Outcomes: Quantitative intraoperative blood loss by gravimetric measurement; total 24-hour blood loss; actual blood loss by Gross formula; hemoglobin and hematocrit changes; uterine tone scores by verbal numerical rating scale (0-10) at 2, 5, and 10 minutes; incidence of postpartum hemorrhage; blood transfusion requirement; hemodynamic profiles; adverse effects.\n\nSample Size: 332 patients (166 per group), non-inferiority margin 10 percentage points, one-sided alpha 0.025, 80% power, estimated baseline event rate 10%, with 15% dropout allowance.",[149,150,151,152],"Postpartum Hemorrhage","Uterine Atony","Cesarean Section","Blood Loss, Surgical",[154,155,156,157,158,159,160,161,162],"Carbetocin","Oxytocin","Uterotonic","Elective Cesarean Delivery","Non-Inferiority Trial","Uterine Tone","Gravimetric Blood Loss","Obstetric Anesthesia","Spinal Anesthesia","2026-06-04",{"date":129,"type":39},{"date":166,"type":22},"2026-08",{"date":168,"type":22},"2028-08",{"name":45,"class":46},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":55,"sex":17,"minAge":84,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":47},"100640918","impact-of-finishingpolishing-systems-on-ormocer-vs-methacrylate-based-bulk-fill-flowable-composite-in-class-v-100640918","NCT07627295","Impact of Finishing\u002FPolishing Systems on Ormocer VS Methacrylate Based Bulk Fill Flowable Composite in Class V","Impact of Finishing\u002FPolishing Systems on Ormocer Versus Methacrylate Based Bulk Fill Flowable Composite in Class V Restorations: Clinical Study and Laboratory Investigations","Inclusion Criteria:\n\n* Three pairs of buccal cervical supragingival carious lesions in anterior teeth\n* Complete and normal occlusion\n* Good oral hygiene\n* Willingness to attend follow-up and recall visits for 2 years\n\nExclusion Criteria:\n\n* Teeth requiring direct pulp capping\n* Poor oral hygiene or failure to complete the oral hygiene phase\n* Chronic periodontitis\n* Pulpitis or non-vital teeth\n* Current orthodontic treatment\n* Presence of parafunctional habits\n* Systemic diseases\n* Previous or ongoing bleaching procedures\n* Smoking patients","35 Years",{"count":7,"type":22},[25],"The goal of this clinical trial is to evaluate and compare. Impact of finishing\u002Fpolishing systems on ormocer versus methacrylate-based bulk-fill flowable composite in Class V restorations: The main question it aims to answer is the following:\n\nAre there any differences between finishing\u002Fpolishing systems on Ormocer versus methacrylate-based bulk-fill flowable composite?",[182],"Class V Restorations",[184,185,186],"Class V restorations;","finishing and polishing;","resin composite","2026-05-31",{"date":163,"type":39},{"date":190,"type":39},"2026-05-12",{"date":192,"type":22},"2028-05",{"name":45,"class":46},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100636899","phase-2-colchicine-for-autoimmune-and-subacute-thyroiditis-100636899","NCT07571681","Colchicine for Autoimmune and Subacute Thyroiditis","Colchicine as a Novel Anti-Inflammatory Strategy in Autoimmune and Subacute Thyroiditis: A Prospective Three-Arm Randomized Controlled Trial","COLTHYR","Inclusion Criteria:\n\n* Age 18 to 70 years\n* Newly diagnosed Hashimoto's thyroiditis or Subacute thyroiditis\n* Diagnosis confirmed clinically, biochemically, and ultrasonographically\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Severe renal impairment\n* Severe hepatic disease\n* Cytopenia\n* Active serious infection\n* Known hypersensitivity to colchicine\n* Chronic corticosteroid use within previous 30 days\n* Participation in another interventional trial\n* Any condition affecting safety or protocol adherence","70 Years",{"count":204,"type":22},300,[116,117],"Thyroiditis includes inflammatory thyroid disorders such as Hashimoto's thyroiditis and subacute thyroiditis. These conditions may cause thyroid pain, neck tenderness, elevated inflammatory markers, thyroid dysfunction, fatigue, and recurrence. Current management includes observation, symptomatic treatment, nonsteroidal anti-inflammatory drugs, and corticosteroids. Although corticosteroids may be effective, relapse after tapering and treatment-related adverse effects remain limitations. Colchicine is hypothesized to reduce inflammatory activity and may improve biochemical and clinical recovery. This study will evaluate the efficacy and safety of low-dose colchicine compared with corticosteroid therapy and supportive care in adults with autoimmune or subacute thyroiditis.",[208,209,210],"Hashimoto Thyroiditis","Subacute Thyroiditis","Thyroiditis",[212,213,214,215,216,217,218,219],"Colchicine","Prednisolone","Autoimmune Thyroiditis","Inflammation","C-reactive protein","ESR","Thyroid Pain","Randomized Trial","2026-05-23",{"date":222,"type":39},"2026-05-28",{"date":224,"type":22},"2026-07",{"date":226,"type":22},"2027-09",{"name":45,"class":46},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":235,"minAge":84,"maxAge":56,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":248,"locationsCount":47},"100635562","efficacy-of-targeted-pelvic-floor-muscle-exercises-for-treatment-of-men-with-primary-post-micturition-dribbling-a-randomized-controlled-trial-100635562","NCT07554300","Efficacy of Targeted Pelvic Floor Muscle Exercises for Treatment of Men With Primary Post Micturition Dribbling: a Randomized Controlled Trial.","PMD","Inclusion Criteria:\n\n* Primary post micturition dribbling\n\nExclusion Criteria:\n\n* Patients with secondary post micturition dribbling (BPH, urethral stricture, urethral diverticulum).\n* Patients with urethral or penile malformations, neurological or chronic major systemic disease.","MALE",{"count":237,"type":22},120,[25],"The goal of this clinical trial is to evaluate the effect of pelvic floor muscle exercises on primary post-micturition dribbling (PMD) in male patients aged 18 to 40 years. The main questions it aims to answer are:\n\n1. Does pelvic floor muscle training reduce the severity and frequency of PMD as measured by the Hallym Post-Micturition Dribble Questionnaire (HPMDQ)?\n2. Does pelvic floor muscle training reduce the amount of post-void residual urine as measured by a post-voiding pad test?\n\nResearchers will compare patients undergoing pelvic floor muscle training (Group A) with those performing non-targeted exercises (Group B) to see if targeted pelvic floor training is more effective in managing PMD symptoms and reducing urine leakage.\n\nParticipants will:\n\n* Undergo random assignment to either pelvic floor muscle training or non-targeted exercise for 12 weeks\n* Complete baseline and follow-up assessments including:\n* Medical history and physical exam\n* Urine analysis and post-void residual measurement\n* International Prostate Symptom Score (IPSS)\n* Post-voiding pad test\n* Hallym Post-Micturition Dribble Questionnaire (HPMDQ)",[241],"Post Micturition Dribble","2026-04-21",{"date":244,"type":39},"2026-04-28",{"date":246,"type":39},"2024-07-01",{"date":38,"type":22},{"name":45,"class":46},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":256,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":4},"100632121","conventional-palatal-crib-versus-bonded-spurs-for-anterior-open-bite-treatment-100632121","NCT07509567","Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment","Conventional Palatal Crib Versus Bonded Spurs in the Treatment of Anterior Open Bite: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Children aged 7 to 12 years\n* Skeletal Class I relationship\n* Angle Class I dental relationship\n* Dental anterior open bite ≥ 1 mm\n* Open bite limited to the anterior segment (incisors and canines)\n* Presence of tongue thrusting habit with anterior tongue posture\n* Patients in mixed dentition stage\n* Fully erupted upper and lower central incisors\n* Fully erupted maxillary first permanent molars\n* Good oral hygiene\n* No gender restrictions\n* Upper arch with no or mild crowding\n\nExclusion Criteria:\n\n* Mouth breathing\n* Skeletal anterior open bite\n* Presence of posterior crossbite\n* Congenitally missing teeth\n* Dental anomalies\n* Presence of any systemic disease","7 Years","12 Years",{"count":259,"type":22},20,[25],"This randomized clinical trial aims to compare the effectiveness and patient acceptance of two orthodontic appliances-conventional palatal crib and bonded spurs-in the treatment of anterior open bite in children.Twenty children aged 7 to 12 years with anterior open bite and Class I skeletal and dental relationships will be randomly assigned to one of two groups The first group will receive a conventional palatal crib appliance fixed to the upper molars, while the second group will receive bonded spurs attached to the palatal surfaces of the upper incisors , All participants will be followed for 6 months. Clinical and digital measurements, including overbite ,The results of this study are expected to help determine which appliance provides better clinical outcomes and higher patient acceptance in the early treatment of anterior open bite.",[263],"Anterior Open Bite",[265],"Anterior Open Bite , Palatal Crib , Bonded Spurs","2026-04-02",{"date":268,"type":39},"2026-04-08",{"date":270,"type":22},"2026-04-01",{"date":272,"type":22},"2026-12-01",{"name":45,"class":46},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":288,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":47},"100629333","phase-4-low-intensity-shockwave-therapy-versus-solifenacin-for-the-treatment-of-overactive-bladder-in-women-100629333","NCT07473310","Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women","Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* OAB symptoms persisting for ≥3 months.\n* OAB Symptom Score (OABSS) ≥7.\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n* Active urinary tract infection.\n* Stress urinary incontinence as primary diagnosis.\n* Pelvic organ prolapse stage ≥II.\n* History of pelvic radiation or surgery within 6 months.\n* Use of anticholinergics or β3-agonists for the past 4 weeks who are unwilling to undergo washout.\n* Pregnancy or breast feeding.\n* Neuropathic diseases or psychological disorders.\n* History of urogenital malignancy.\n* Uncontrolled DM (HbA1c \\> 6.8)\n* Uncorrected coagulopathy or severe cardiovascular disease.\n* Contraindication to solifenacin e.g.: closed angle glaucoma)",{"count":282,"type":22},70,[146],"The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women.\n\nThe main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of life, and whether these improvements are sustained over a 12-month follow-up period, compared with standard medical therapy.\n\nResearchers will compare Li-SWT with oral solifenacin succinate, a commonly used antimuscarinic medication for OAB.\n\nParticipants will be randomly assigned to receive either Li-SWT once weekly for 8 weeks or solifenacin 5 mg taken orally once daily for 12 months. All participants will complete symptom questionnaires and three-day voiding diaries and will undergo uroflowmetry, post-void residual measurement, and filling cystometry at specified time points during follow-up.",[286,287],"Overactive Bladder (OAB)","Urge Incontinence",[289,290,291,292],"OAB","overactive bladder","low intensity shockwave","solifenacin","2026-03-10",{"date":295,"type":39},"2026-03-16",{"date":297,"type":39},"2025-11-11",{"date":299,"type":22},"2027-12",{"name":45,"class":46},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":177,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":318,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":47},"100620187","effect-of-oketani-breast-massage-on-promoting-breastfeeding-100620187","NCT07354360","Effect of Oketani Breast Massage on Promoting Breastfeeding","Effect of Oketani Massage on Successful Breastfeeding","OKETANI-BF","inclusion criteria:\n\n1. Age between 18 and 35 years\n2. Singleton pregnancy\n3. Term gestation (\\>37-40 weeks).\n4. Women willing to breast feed\n5. The woman will deliver by cesarean section and has relative with her\n6. Absence of maternal physical and\u002F or mental illness that prevents breastfeeding.\n\nThe exclusion criteria include:\n\n1. Women with breast problems such as breast tumors, breast surgery and nipple problems\n2. Women have obstetric complications as postpartum hemorrhage.\n3. Neonatal problems",{"count":310,"type":22},100,[25],"Breastfeeding is essential for infant survival and maternal health; however, many primipara women experience breastfeeding difficulties in the early postpartum period, particularly, latching difficulties, ineffective milk transfer, low breastfeeding self-efficacy and breast engorgement, which may compromise successful breastfeeding. Oketani massage is a non-pharmacological, cost-effective breast massage technique developed to enhance milk flow, improve maternal comfort during breastfeeding and reduce breast engorgement. This study aims to evaluate effect of Oketani massage on successful breastfeeding. Successful breastfeeding will be assessed through indicators of maternal latching technique, successful breastfeeding behavior and maternal breastfeeding self-efficacy. The findings of this study may support the use of Oketani massage as a supportive nursing intervention to promote successful breastfeeding outcomes in the early postpartum period",[314,315,316,317],"Breastfeeding","Breastfeeding Self-Efficacy","Oketani Massage","Latching",[314,319,320,321,322],"Oketani massage","breastfeeding self-efficacy","breast engorgement","Feeding Behavior","2026-03-07",{"date":293,"type":39},{"date":326,"type":22},"2026-02",{"date":328,"type":22},"2026-12",{"name":45,"class":46},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":83,"minAge":18,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":347,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":356,"locationsCount":47},"100612953","effect-of-an-educational-session-for-abortive-women-on-maternity-nurses-practices-100612953","NCT07260279","Effect of an Educational Session for Abortive Women on Maternity Nurses' Practices","Effect of Educational Sessions for Abortive Care on Maternity Nurses' Performance","EESAW-MNP","Inclusion Criteria:\n\nRegistered maternity nurses working in obstetrics or gynecology departments.\n\nHaving at least one year of clinical experience in maternity or reproductive health units.\n\nWilling to participate and provide informed consent.\n\nAble to read and understand the educational materials provided.\n\nPresent at the workplace during the study and follow-up periods.\n\nNot previously involved in similar abortion care training programs.\n\nExclusion Criteria:\n\nNurses on maternity or annual leave during the study period.\n\nAdministrative or non-clinical nursing staff.\n\nNurses with less than one year of professional experience.\n\nRefusal to participate or withdrawal at any stage of the study.\n\nAttendance of any concurrent external training on abortion or reproductive health during the study.\n\nIncomplete participation in the educational intervention sessions.","60 Years",{"count":340,"type":22},60,[25],"The goal of this study is to evaluate the effect of structured educational sessions for abortive women on the practices of maternity nurses.\n\nThe study aims to enhance nurses' clinical skills and patient care related to abortion management.\n\nParticipants will:\n\nAttend educational sessions designed to improve nursing practices\n\nParticipate in activities and discussions led by experienced instructors\n\nBe observed before and after the sessions to assess changes in clinical practices\n\nThe study will compare nursing practices before and after the intervention to determine the overall impact of the educational sessions on professional performance and patient care quality.",[344,345,346],"Abortion","Practice","Maternity",[344,348,349],"Maternity nurses","Practices","2026-02-28",{"date":352,"type":39},"2026-03-03",{"date":354,"type":22},"2026-02-01",{"date":328,"type":22},{"name":45,"class":46},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":55,"sex":83,"minAge":18,"maxAge":177,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":47},"100612055","emergency-obstetric-care-protocol-100612055","NCT07248605","Emergency Obstetric Care Protocol","Effect of Applying Emergency Obstetric Care Protocol on Maternity Nurses' Practices","Inclusion Criteria:\n\n* of maternity nurses who are works in Obstetric departments , Emergency obstetric operating room and delivery unit\n\nExclusion Criteria:\n\n* nurses who are on long vocations at the time of data collection or have administrative work.",{"count":340,"type":22},[25],"This study aims to investigate the effect of applying emergency obstetric care protocol on maternity nurses' practices.",[368,369],"Emergency Care","Obstetric",{"date":352,"type":39},{"date":372,"type":22},"2026-03-01",{"date":374,"type":22},"2027-01-01",{"name":45,"class":46},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":397,"leadSponsor":399,"locationsCount":47},"100625984","phase-3-efficacy-of-gabapentin-combined-with-solifenacin-for-non-neurogenic-overactive-bladder-in-women-100625984","NCT07429734","Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women","Efficacy and Tolerability of Solifenacin Combined With Gabapentin Versus Solifenacin Monotherapy for the Treatment of Non-neurogenic Overactive Bladder in Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Overactive bladder symptom score (OABSS) \\> 5, urgency subscore ≥3, and urge incontinence score≥ 2.\n\nExclusion Criteria:\n\n* Active urinary tract infection\n* Neurogenic bladder\n* History of genitourinary malignancy\n* Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI\n* Any psychological or psychiatric disorders",{"count":340,"type":22},[117],"The goal of the study is to compare the efficacy, safety and tolerability of solifenacin plus gabapentin versus solifenacin monotherapy for the treatment of women who are suffering from non-neurogenic ОАВ.\n\nThe main questions it aims to answer are:\n\nDoes combination of Solifenacin and Gabapentin affect the total score and sub-scores of OABSS in females with non-neurogenic ОАВ ? What medical problems do participants have when taking combination of Solifenacin and gabapentin ?",[387],"Overactive Bladder",[290,389,390,292,391,392],"non-neurogenic","gabapentin","anticholinergic","Randomized Controlled Trial","2026-02-23",{"date":395,"type":39},"2026-02-24",{"date":326,"type":22},{"date":398,"type":22},"2027-01",{"name":45,"class":46},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":202,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":410,"briefSummary":411,"conditions":412,"keywords":415,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":4},"100604034","comparison-of-milrinone-and-epinephrine-on-tapse-100604034","NCT07144267","Comparison of Milrinone and Epinephrine on TAPSE","Milrinone Versus Epinephrine for Right Ventricular Dysfunction After Cardiac Surgery in Adults: A Randomized Double-Blinded Trial","Milrinone","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status II \\& III\n* Age between 18 and 70 years\n* Both Gender\n* Body mass index less than 40 kg\u002Fm2\n* Ejection fraction of \\>40%\n* Tricuspid annular plane systolic excursion (TAPSE) \\\u003C 1.7cm\n\nExclusion Criteria:\n\n* Patient refusal.\n* Preoperative RV impairment\n* Pulmonary hypertension (estimated pulmonary artery systolic pressure \\> 50 mmHg)\n* Patients with any contraindications to Transesophageal echocardiography (TEE)\n* Redo or Re-exploration surgery\n* Patients with chronic kidney disease (serum creatinine \\> 1.5 mg\u002F dl)\n* Patients with chronic liver disease (child pugh B and C)",{"count":409,"type":22},102,[25],"Cardiopulmonary bypass (CPB) is a critical technology in cardiac surgery, allowing for the temporary replacement of the heart and lung functions during intricate surgical procedures. it has significant post-surgical complications, the most important complications of CPB is right ventricle (RV) dysfunction. Diagnosis and management of RV dysfunction is crucial for maintenance of hemodynamic stability and organ function in early post-operation period and prognostic for later phase.",[413,414],"Cardiac Anaesthesia","Cardiopulmonary Bypass",[416,417],"Cardiopulmonary bypass (CPB) -Tricuspid annular plane systolic excursion (TAPSE)-","Epinephrine - Milrinone",{"date":419,"type":39},"2026-02-25",{"date":372,"type":22},{"date":422,"type":22},"2028-03-30",{"name":45,"class":46},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":23,"phases":433,"briefSummary":434,"conditions":435,"keywords":438,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":449,"locationsCount":47},"100626480","phase-4-mitochondrial-redox-modulation-in-newly-diagnosed-type-2-diabetes-a-randomized-controlled-trial-comparing-imeglimin-vs-metformin-monotherapy-100626480","NCT07436182","Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy","MIRROR-DM",".1 Inclusion Criteria\n\nParticipants must meet ALL of the following criteria for enrollment:\n\n1. Age 18 or more inclusive, male or female.\n2. Confirmed diagnosis of T2DM within the preceding 12 months prior to screening, established by ADA or WHO criteria: fasting plasma glucose ≥ 126 mg\u002FdL on two separate occasions, and\u002For 2-hour OGTT plasma glucose ≥ 200 mg\u002FdL, and\u002For HbA1c ≥ 6.5%, and\u002For random plasma glucose ≥ 200 mg\u002FdL with classic hyperglycemic symptoms.\n3. HbA1c between 6.5% and 7.5 % inclusive at screening.\n4. Treatment-naive: no prior antidiabetic pharmacological treatment, or any prior antidiabetic treatment discontinued at least 3 months before screening.\n5. Estimated glomerular filtration rate (eGFR) ≥ 45 mL\u002Fmin\u002F1.73m² by CKD-EPI formula at screening.\n6. Willing and able to provide written informed consent in Arabic or English.\n7. Able to attend all scheduled study visits and comply with study procedures, dietary restrictions, and pre-analytical blood collection requirements.\n\n2 Exclusion Criteria\n\nParticipants meeting ANY of the following criteria will be excluded:\n\n1. Type 1 diabetes mellitus, Latent Autoimmune Diabetes in Adults (LADA), or other specific types of diabetes (anti-GAD antibody positivity, monogenic diabetes).\n2. HbA1c \\>7.5 gm%\n3. eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m² - increase risk of drug accumulation and lactic acidosis.\n4. Hepatic impairment defined as ALT or AST \\> 2.5 times the upper limit of normal at screening. Hepatic dysfunction independently elevates plasma lactate by impairing lactate clearance and pyruvate metabolism, confounding the primary endpoint.\n5. History of or current congestive heart failure (NYHA Class III-IV) or clinically significant cardiovascular disease with hemodynamic instability major risk factor for lactic acidosis and a confound for tissue lactate metabolism.\n6. Active or recent (within 3 months) use of any antidiabetic pharmacological agent.\n7. Current use of medications known to significantly affect mitochondrial function or lactate\u002Fpyruvate metabolism: valproate, linezolid, nucleoside reverse transcriptase inhibitors (NRTIs), phenformin, zidovudine, or high-dose thiamine-depleting regimens.\n8. Pregnancy, planned pregnancy within the trial period, or active breastfeeding.\n9. Active malignancy requiring chemotherapy, radiotherapy, or immunosuppression within the preceding 6 months.\n10. Significant chronic alcohol use: \\> 21 units per week (male) or \\> 14 units per week (female). Alcohol is a major independent confound for pyruvate\u002Flactate ratio through its own effects on hepatic NAD+\u002FNADH balance.\n11. Acute illness, surgery, trauma, or hospitalization within 4 weeks of screening, acute physiological stress elevates plasma lactate independent of drug effects.\n12. Vigorous or unaccustomed physical exercise within 24 hours of any biomarker blood draw, exercise-induced lactate elevation is a major pre-analytical confound.\n13. Known hypersensitivity or contraindication to imeglimin or metformin.\n14. Participation in another interventional clinical trial within 3 months preceding screening.\n15. Any condition that, in the investigator's judgment, would render the patient unable to safely complete the trial or reliably provide valid biomarker samples.",{"count":432,"type":22},176,[146],"he goal of this clinical trial is to compare the mitochondrial redox effects of imeglimin versus metformin monotherapy in adults with newly diagnosed Type 2 diabetes mellitus who are treatment-naive. The main questions it aims to answer are:\n\nDoes imeglimin improve the fasting plasma pyruvate\u002Flactate ratio (a validated surrogate of mitochondrial NAD⁺\u002FNADH redox balance) to a greater extent than metformin after 12 weeks of treatment? Does imeglimin produce more favorable changes in secondary mitochondrial and glycemic biomarkers - including fasting plasma lactate, fasting plasma pyruvate, HbA1c, HOMA-IR, and lipid profile - compared to metformin?\n\nResearchers will compare imeglimin 1000 mg twice daily to metformin up to 1000 mg twice daily to see if imeglimin produces superior improvement in mitochondrial oxidative capacity and cytoplasmic redox balance, reflected by a greater increase in the fasting plasma pyruvate\u002Flactate ratio, without compromising glycemic efficacy or safety.\n\nParticipants will:\n\nTake either imeglimin 1000 mg twice daily or metformin (titrated up to 1000 mg twice daily) orally for 12 weeks, as assigned by randomization Attend clinic visits at baseline (Week 0) and at Week 12 for fasting blood sample collection, including strict bedside deproteinization of pyruvate samples using ice-cold perchloric acid to ensure analytical accuracy Undergo measurement of fasting plasma pyruvate\u002Flactate ratio, HbA1c, HOMA-IR, fasting glucose, fasting insulin, fasting plasma lactate, fasting plasma pyruvate, and full lipid profile at both visits Be monitored for adverse events and safety parameters, including renal function (eGFR), throughout the study period",[436,437],"Mitochondria","Metformin",[439,440,437,441,442],"type 2 diabetes","Imeglimin","Pyruvate\u002FLactate ratio","Mitochondrial redox","2026-02-21",{"date":445,"type":39},"2026-02-27",{"date":372,"type":22},{"date":448,"type":22},"2026-06-01",{"name":45,"class":46},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":478,"locationsCount":479},"100625002","phase-4-randomized-controlled-trial-comparing-low-dose-tadalafil-versus-solifenacin-for-management-of-overactive-bladder-in-women-multicenter-egyptian-national-study-100625002","NCT07416968","Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study","Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study (WoMEN'S)","WoMEN'S","Inclusion Criteria:\n\n* OAB symptoms persisting for ≥3 months\n* OAB Symptom Score (OABSS) \\> 5 and urgency sub-score of OABSS ≥ 2\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* Active urinary tract infection.\n* Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI\n* Pelvic organ prolapse stage ≥II according to POP-Q system.\n* History of pelvic radiation.\n* History of neurosurgical interventions.\n* Pregnancy or breastfeeding.\n* Neuropathic diseases affecting the lower urinary tract.\n* History of genitourinary malignancy.\n* Post-void residual urine (PVR) \\> 150 ml.\n* Vesical or lower ureteric stones.\n* Uncontrolled diabetes mellitus (HbA1c \\> 7).\n* Any psychological or psychiatric disorders.\n* Contraindications or allergy to the used medications.\n* History of surgeries in the urinary bladder.\n* History of pelvic surgeries within 6 months.\n* Voiding dysfunctions.","75 Years",{"count":460,"type":22},480,[146],"Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage.\n\nWomen who join the study will be randomly placed into one of two groups:\n\nOne group will take tadalafil (5 mg), a medicine taken once a day.\n\nThe other group will take solifenacin (5 mg), a common treatment for OAB, also taken once a day.\n\nThe study will last 12 weeks. Participants will keep a bladder diary, answer short questionnaires, and have simple urine flow and bladder tests at several visits.\n\nThe main goal is to find out which medicine lowers OAB symptoms more, such as urgency and frequent urination. Researchers will also look at quality of life, bladder function, and side effects.\n\nWomen aged 18 to 75 years with OAB symptoms for at least 3 months may be able to take part.",[286,464],"Overactive Bladder Syndrome",[387,289,466,467,468,469,470,471],"Tadalafil","Solifenacin","Low dose tadalafil","Urgency","frequency","Urge Urinary Incontinence","2026-02-17",{"date":474,"type":39},"2026-02-18",{"date":476,"type":39},"2025-09-01",{"date":328,"type":22},{"name":45,"class":46},14,{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":83,"minAge":488,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":47},"100536367","stellate-ganglion-block-for-prevention-of-post-mastectomy-depression-100536367","NCT06263907","Stellate Ganglion Block for Prevention of Post Mastectomy Depression","Preemptive Efficacy of Stellate Ganglion Block for Prevention of Post Mastectomy Depression","SGB","Inclusion Criteria:\n\n* Female patients\n* Age ranging from 18 to 65 years\n* American Society of Anesthesiologists (ASA) no more than II\n* Had unilateral cancer breast\n* Scheduled to do unilateral modified radical mastectomy\n\nExclusion Criteria:\n\n* Pregnant female\n* Existing Horner syndrome\n* Had any neuromuscular disease\n* Had allergy to local anesthetics\n* History of use of analgesics\n* Had any deformity or a previous surgery in the neck or ipsilateral arm or breast\n* Had any contraindication to the procedure (coagulation disorders, local infection, sepsis)\n* Had any contraindication to the sympathetic blockade (decompensate cardiopulmonary or hemodynamic disorders)\n* History of psychotic disorder including depression, bipolar disorder or personality disorder\n* Patient with Beck Depression Inventory (BDI) score more than 13","21 Years","65 Years",{"count":491,"type":22},140,[25],"Complications after mastectomy include chronic pain and depression.",[495,496,497],"Mastectomy","Pain, Acute","Pain, Chronic","2026-02-15",{"date":472,"type":39},{"date":501,"type":39},"2024-03-01",{"date":503,"type":22},"2028-12-30",{"name":45,"class":46},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":338,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":47},"100510363","maxillary-and-mandibular-nerve-block-100510363","NCT05925465","Maxillary and Mandibular Nerve Block","Effect of Combined Maxillary and Mandibular Nerve Block on Orthognathic Surgery Outcomes","nerve block","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) I\u002FII patients,\n* within the age group of 21-60 years\n* both sex\n* scheduled for elective faciomaxillary surgery\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Patients with polytrauma\n* Patients necessitating postoperative ventilation\n* Oral or facial infection\n* Coagulopathy\n* Drug intake for chronic pain\n* Known allergy to the study drugs\n* Psychiatric disorder",{"count":340,"type":22},[25],"Mandibular fractures are among the most common (60-70%) maxillofacial fractures observed in emergency rooms. In the closed reduction (non-surgical), the bone fragments are realigned manually or by using traction devices. The open reduction surgery of mandibular fractures should first ensure the restoration of the occlusion of the mandible to prevent postoperative malocclusion, followed by stabilization by means of rigid fixations such as plates, screws, and rigid intermaxillary blocks in order to minimise any nonunion, malunion, or delayed union of the fracture segments. These surgical procedures are associated with moderate postoperative pain, being the first 24 hours the most intense pain period. Maxillary and mandibular nerve blocks are performed in patients with refractory trigeminal neuralgia. However, there have been few studies evaluating the analgesic effects of these blocks for maxillofacial surgeries.",[517],"Analgesia",{"date":472,"type":39},{"date":520,"type":39},"2023-08-01",{"date":522,"type":22},"2028-03-31",{"name":45,"class":46},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":47},"100503784","predicting-post-extubation-stridor-after-maxillomandibular-fixation-100503784","NCT05839756","Predicting Post Extubation Stridor After Maxillomandibular Fixation","Predicting Post Extubation Stridor in Patients With Intermaxillary Fixation","airway","Inclusion Criteria:\n\n* Adult patients (\\>18 years)\n* American Society of Anesthesiologists status I and II\n* undergoing elective maxillomandibular fixation surgeries under general anesthesia with nasal endotracheal intubation\n\nExclusion Criteria:\n\n* patients' refusal\n* pregnant females\n* patients with body mass index \\\u003C18.5 or ≥ 35 kg\u002Fm2\n* risk of aspiration\n* cardiorespiratory disorder\n* neuromuscular disease\n* uncontrolled diabetes mellitus\n* gastrointestinal bleeding\n* on chronic steroid therapy\n* intubated patients or were intubated or had upper airway infection within 1 week prior to surgery\n* history of any pathology, radiotherapy or surgery in the neck\n* had difficult laryngeal US plane (as neck wound)",{"count":533,"type":22},62,[25],"Endotracheal intubation can induce laryngotracheal injury which results in narrowing of the airway due to edema of the glottis. This can increase the risk of development of post-extubation stridor (PES)",[537,538],"Stridor","Larynx Edema",{"date":472,"type":39},{"date":541,"type":39},"2023-05-03",{"date":543,"type":22},"2028-06-30",{"name":45,"class":46},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":83,"minAge":553,"maxAge":56,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":47},"100499601","neostigmine-as-an-adjuvant-in-tranversus-abdominis-plane-tap-block-in-cesarean-section-under-spinal-anesthesia-100499601","NCT05785377","Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia","Efficacy of Neostigmine as an Adjuvant to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block as a Postoperative Analgesia After Caesarean Delivery.","TAB","Inclusion Criteria:\n\n* Age from 19 to 40 years old\n* American Society of Anesthesiologists (ASA) physical status II patients\n* Singleton pregnancies with a gestational age of at least 37 weeks.\n* Patients undergoing spinal anesthesia for cesarean delivery via a Pfannenstiel incision with exteriorization of the uterus.\n\nExclusion Criteria:\n\n* Age \\\u003C 19 or \\> 40 years.\n* Height\\\u003C150 cm, weight \\\u003C 60 kg, body mass index (BMI) ≥40 kg\u002Fm2.\n* Inability to comprehend or participate in the pain scoring system.\n* Contraindications to spinal anesthesia (Coagulopathy, increased intracranial pressure, or local skin infection).\n* Hypersensitivity to any drug used in the study.\n* Any hypertensive disorders of pregnancy.\n* Renal impairment or other contraindications to non-steroidal anti-infilamatory drugs (NSAIDS).\n* Significant cardiovascular, renal or hepatic abnormalities.\n* Patients with history of opioid intake, drug abusers or psychiatric patients","19 Years",{"count":555,"type":22},58,[25],"Cesarean birth is a common surgical procedure. After cesarean birth, postsurgical pain may delay recovery, interfere with maternal-newborn bonding, and reduce the breastfeeding if not adequately controlled. Postpartum analgesia has become a common concern.\n\nMany adjuvant drugs used for peripheral nerve blocks as( N-methyl-d-aspartate (NMDA) receptor antagonists , Magnesium , Ephedrine , Dexamesathone , Fentanyl , Midazolam and Neostigmine) The potential of neostigmine as an adjuvant in peripheral nerve block is through its action to increase acetylcholine at muscarinic junctions of peripheral nerves. 500 mcg neostigmine was used as adjuvant to local anesthetic in an axillary brachial plexus block leads to decreased pain and less use of analgesics in the first 24 hours postoperatively with no incidence of adverse effects.",[517],{"date":472,"type":39},{"date":561,"type":22},"2027-12-01",{"date":563,"type":22},"2029-12-01",{"name":45,"class":46},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":553,"maxAge":338,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":575,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":47},"100481037","ketorolac-intravenous-regional-analgesia-in-lower-limb-surgeries-100481037","NCT05543785","Ketorolac Intravenous Regional Analgesia in Lower Limb Surgeries","Ketorolac for Intravenous Regional Analgesia in Lower Limb Orthopedic Surgeries Under Spinal Anesthesia: A Randomized Control Study","K-IVRAg","Inclusion Criteria:\n\n* American Society of Anesthesiologists physical status I or II\n* Elective unilateral lower limb orthopedic surgery with tourniquet under spinal anesthesia\n\nExclusion Criteria:\n\n* Pregnant females\n* Body mass index ≥ 35 kg\u002Fm2\n* Allergy to ketorolac\n* Had renal, asthmatic, vascular (Raynaud's syndrome) disease, hematological anemias\n* Had any history of gastrointestinal tract inflammation, bleeding, ulceration, or perforation besides\n* Edema in the operated limb grade ≥ 3",{"count":574,"type":22},76,[25],"Tourniquet, a compressing device, otherwise its use in intravenous regional anesthesia, is commonly used in particular orthopedic surgeries. From the previous documented effectiveness and safety of intravenous (IV) administration of ketorolac in the circulatory-isolated limb as a part of intravenous regional anesthesia; we hypothesized that in orthopedic surgeries done with tourniquet, intravenous (IV) administration of ketorolac after tourniquet inflation, will act as intravenous regional analgesia. So, it will prolong the postoperative analgesic duration as a primary outcome.",[578],"Postoperative Pain, Acute",[580,581,582,583,584],"ketorolac","randomized controlled trial","intravenous regional anesthesia","lower limb","orthopedic surgeries",{"date":472,"type":39},{"date":587,"type":39},"2022-11-01",{"date":589,"type":22},"2027-12-30",{"name":45,"class":46},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":17,"minAge":598,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":23,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":47},"100603493","botulinum-toxin-injection-in-reducing-scar-following-cheilorrhaphy-100603493","NCT07137234","Botulinum Toxin Injection in Reducing Scar Following Cheilorrhaphy.","Efficacy of Botulinum Toxin Injection in Reducing Scar Following Cheilorrhaphy: A Randomized Controlled Clinical Trial.","inclusion criteria :\n\n* patients with mild to severe unilateral cleft lip requiring repair\n* free from any systemic disease\n* with or without cleft palate\n* fit for general anesthesia exclusion criteria :\n* patients with syndromic type of cleft lip\n* patients with systemic disease","10 Weeks",{"count":600,"type":22},32,[25],"the aim of the study will be directed to evaluate clinically the effect of botulinum toxin type A injection on reducing the scar following cleft lip surgical repair.",[604],"Unilateral Cleft Lip",[606,607,608],"botulinum toxin","cleft lip","scar","2026-02-07",{"date":611,"type":39},"2026-02-10",{"date":613,"type":39},"2025-03-15",{"date":615,"type":22},"2026-05",{"name":45,"class":46},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":23,"phases":626,"briefSummary":627,"conditions":628,"keywords":631,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":4},"100623172","efficacy--safety-of-high-power-vs-low-power-holmium-laser-in-mini-pcnl-for-large-renal-stones-100623172","NCT07393178","Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones","High Pulse Power vs. Low Pulse Power Holmium: YAG Laser in Mini-Percutaneous Nephrolithotomy for Management of Renal Stones > 20 mm: A Randomized Controlled Trial","miniPCNL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Renal Stones \\\u003C 20 mm indicated for intervention (pain, infection, obstructing stone causing hydronephrosis or parenchymal affection)\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Active urinary tract infection\n* Bleeding diathesis\n* Pregnancy\n* Anatomical anomalies impeding access e.g. ectopic malrotated kidneys, crossed fused kidneys...etc.)",{"count":282,"type":22},[25],"The investigator will compare between holmium laser setting during miniPCNL for renal stones as regard safety \\& efficacy",[629,630],"Renal Stones","Renal Calculi > 2 cm",[632,633,634],"mini-PCNL","holmium-YAG","laser lithotripsy","2026-02-04",{"date":637,"type":39},"2026-02-06",{"date":639,"type":22},"2026-03-15",{"date":641,"type":22},"2027-01-30",{"name":45,"class":46},{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":235,"minAge":488,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":23,"phases":652,"briefSummary":653,"conditions":654,"keywords":656,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":669},"100623049","phase-4-daily-tadalafil-5-mg-combined-with-on-demand-sildenafil-100-mg-for-treatment-of-erectile-dysfunction-in-pde-5i-non-responder-patients-100623049","NCT07391579","Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients","Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients: A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Sexually active male.\n* History of ED for ≥6 months.\n* Erectile function domain of IIEF-15 score \\\u003C17.\n* Documented failure to respond to PDE-5I \\[definition of non-responder patients are patients with ED who don't respond to maximum dose of PDE-5I on ≥4 occasions in spite of accurate timing and good sexual stimulation\\].\n* Stable sexual relationship ≥ 6 months.\n\nExclusion Criteria:\n\n* Penile anatomical deformities or Peyronie's disease.\n* Pelvic surgery or radiation.\n* Active malignancy or severe systemic illness.\n* Previous penile surgery of any kind, such as penile prosthesis, penile lengthening, penile cancer surgery, penile plication or grafting.\n* Contraindication to PDE5i (High risk cardiac patients, patients on nitrates, hypotension).\n* Using other treatments for ED e.g., Intra-cavernoasl prostaglandin injection therapy.",{"count":651,"type":22},500,[146],"The goal of this clinical trial is to evaluate whether daily dosing with tadalafil 5 mg combined with on-demand sildenafil 100 mg can improve erectile function in men with erectile dysfunction (ED) who do not respond to PDE5 inhibitor alone.\n\nThe main questions it aims to answer are:\n\n* Does the combination of daily tadalafil and on-demand sildenafil lead to a greater improvement in erectile function (measured by the IIEF-EF domain) compared with on-demand sildenafil alone?\n* Is the combination therapy safe and well tolerated in this patient population?\n\nResearchers will compare:\n\n* Group A: Daily tadalafil 5 mg plus on-demand sildenafil 100 mg\n* Group B: Daily placebo plus on-demand sildenafil 100 mg\n\nto determine whether the combination regimen provides superior improvement in erectile function and patient satisfaction.\n\nParticipants will:\n\n* Undergo baseline assessment including medical history, physical examination, and laboratory tests.\n* Be randomly assigned to one of the two treatment groups.\n* Take the assigned medications for 12 weeks.\n* Complete follow-up evaluations at 4, 8, and 12 weeks, including:\n\nInternational Index of Erectile Function (IIEF-15) questionnaire Erection Hardness Score (EHS) assessment Reporting of any adverse effects",[655],"Erectile Dysfunctions",[657,658,659,466,660,661],"Erectile Dysfunction","ED","Sildenafil","PDE5i Non-Responders","Combination Therapy","2026-02-02",{"date":637,"type":39},{"date":665,"type":39},"2025-12-01",{"date":667,"type":22},"2027-06",{"name":45,"class":46},11,""]